uniQure N.V. Deferred Tax Assets, Deferred Income
uniQure N.V. (QURE) had Deferred Tax Assets, Deferred Income of $6.68 million as of 2019-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2021-03-01
- 2019-12-31: Deferred Tax Assets, Deferred Income $6.68M.
- 2018-12-31: Deferred Tax Assets, Deferred Income $7.48M.
- 2017-12-31: Deferred Tax Assets, Deferred Income $17.93M.
- 2016-12-31: Deferred Tax Assets, Deferred Income $20.00M.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2019-12-31 | $6.68M 10-K · filed 2021-03-01 |
| 2018-12-31 | $7.48M 10-K · filed 2020-03-02 |
| 2017-12-31 | $17.93M 10-K · filed 2019-02-28 |
| 2016-12-31 | $20.00M 10-K · filed 2018-03-14 |
| 2015-12-31 | $21.41M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |